Sign In
Buy MIRM
$91.84
-0.335 (-0.363%)
At Close: Jun 03, 2026
FOSTER CITY, Calif. & YONGIN, South Korea--(BUSINESS WIRE)--Mirum and GC Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in South Korea
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:00pm, Monday, 12'th Jul 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals to Present at Piper Sandler's Virtual EASL Takeaway Day
04:05pm, Thursday, 24'th Jun 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at Piper Sandler's Virtual EASL Takeaway Day
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Thursday, 10'th Jun 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Showcases Maralixibat Transplant-Free Survival Data for PFIC and Long-Term Safety Analyses for Alagille Syndrome during WCPGHAN Annual Meeting
Mirum Is Undervalued Despite Expected Tough Competition
02:43pm, Tuesday, 01'st Jun 2021
Mirum aims to be a leader in the treatment of rare liver diseases for which the unmet medical need is high.
Mirum: Rare Disease Play With Upcoming Catalysts
08:00am, Tuesday, 18'th May 2021
Mirum: Rare Disease Play With Upcoming Catalysts
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:00pm, Monday, 10'th May 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals' (MIRM) CEO Chris Peetz on Q1 2021 Results - Earnings Call Transcript
02:51pm, Sunday, 09'th May 2021
Mirum Pharmaceuticals' (MIRM) CEO Chris Peetz on Q1 2021 Results - Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Lags Revenue Estimates
09:02pm, Thursday, 06'th May 2021
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -150.75% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for t
Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal
05:29pm, Monday, 03'rd May 2021
CANbridge will make a $10 million upfront payment for the two Fabry and Pompe candidates. Guangzhou Link Health Pharma and Australia's George Clinical plan to form a China clinical CRO JV that will co
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Monday, 12'th Apr 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:00pm, Wednesday, 10'th Mar 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Lags Revenue Estimates
06:11pm, Tuesday, 09'th Mar 2021
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -150.88% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead fo
Mirum Pharmaceuticals Honors Alagille Syndrome Awareness Day with Launch of Disease Awareness Campaign
09:00am, Sunday, 24'th Jan 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Honors Alagille Syndrome Awareness Day with Launch of Disease Awareness Campaign
